Stay updated on CIN-107 in Primary Aldosteronism Clinical Trial
Sign up to get notified when there's something new on the CIN-107 in Primary Aldosteronism Clinical Trial page.

Latest updates to the CIN-107 in Primary Aldosteronism Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedRevision: v3.5.0 added; Revision: v3.4.3 removed.SummaryDifference0.1%

- Check20 days agoChange DetectedPage revision updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check27 days agoChange DetectedResults were posted for CIN-107 in adults with primary aldosteronism, including treatment-emergent adverse events, 12-week SBP/DBP changes, BP response rates, and pharmacodynamic marker responses (Part 1). Previously listed safety and efficacy data elements were removed from the page.SummaryDifference3%

- Check48 days agoChange DetectedAdded Revision: v3.4.2; removed the funding/operating-status notice and the previous Revision: v3.4.1.SummaryDifference0.4%

- Check55 days agoChange DetectedAdded a government funding notice about potential delays and status updates, and updated the page revision from v3.4.0 to v3.4.1.SummaryDifference0.4%

- Check62 days agoChange DetectedNew UI element 'Show glossary' and a v3.4.0 metadata revision with adjusted QC criteria labeling and FEAR Act data visibility have been introduced. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

Stay in the know with updates to CIN-107 in Primary Aldosteronism Clinical Trial
Enter your email address, and we'll notify you when there's something new on the CIN-107 in Primary Aldosteronism Clinical Trial page.